» Articles » PMID: 35694702

Maximizing Quality of Life Remains an Ultimate Goal in the Era of Precision Medicine: Exemplified by Lung Cancer

Overview
Journal Precis Clin Med
Specialty General Medicine
Date 2022 Jun 13
PMID 35694702
Authors
Affiliations
Soon will be listed here.
Abstract

An ultimate goal of precision medicine in lung cancer treatment is to restore patient health with maximized quality of life (QOL). Results from Mayo Clinic studies show that a significant improvement in fatigue, dyspnea, and pain scales could lead to better overall QOL. Although treatments and guidelines for clinical implementation to alleviate these key symptoms are available, few cancer patients receive adequate therapy, mostly because of limitations in current care delivery systems and unclear clinicians' roles. For optimal care of lung cancer survivors in different subpopulations, three barriers must be overcome: physicians' lack of knowledge, unwarranted practice variation, and uncertainty regarding care provider roles. Appropriate culturally adapted, tested and validated tools for QOL measures must be developed, rather than directly translating existing tools between different languages and across cultures or diverse subpopulations. Finally, lack of sensitive, adequate, and relevant tools in measuring health-related QOL (HRQOL) has long been an issue for effective data collection, demanding a global consensus on a set of core components that reflect the needs of all critical parties for the best cure and care, supporting patients to achieve optimal HRQOL.

Citing Articles

Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.

Kumar A, Owen J, Sloat N, Maynard E, Hill V, Hubbard C Curr Oncol. 2024; 31(11):7244-7257.

PMID: 39590164 PMC: 11593073. DOI: 10.3390/curroncol31110534.


Editorial: Application of plant secondary metabolites to pain neuromodulation, volume III.

Singla R, Guimaraes A, Zengin G Front Pharmacol. 2023; 14:1166272.

PMID: 36895948 PMC: 9990135. DOI: 10.3389/fphar.2023.1166272.


Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With -Positive Advanced NSCLC.

Wu Y, Lu S, Yang J, Zhou J, Seto T, Ahn M JTO Clin Res Rep. 2022; 3(10):100406.

PMID: 36247019 PMC: 9558051. DOI: 10.1016/j.jtocrr.2022.100406.


Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II.

Singla R, Guimaraes A, Zengin G Front Pharmacol. 2022; 13:1013063.

PMID: 36225584 PMC: 9549320. DOI: 10.3389/fphar.2022.1013063.


A Clinical Decision Support System for the Prediction of Quality of Life in ALS.

Antoniadi A, Galvin M, Heverin M, Wei L, Hardiman O, Mooney C J Pers Med. 2022; 12(3).

PMID: 35330435 PMC: 8955774. DOI: 10.3390/jpm12030435.


References
1.
Piderman K, Sytsma T, Frost M, Novotny P, Rausch Osian S, Solberg Nes L . Improving Spiritual Well-Being in Patients with Lung Cancers. J Pastoral Care Counsel. 2015; 69(3):156-62. PMC: 4800747. DOI: 10.1177/1542305015602711. View

2.
Cheville A, Novotny P, Sloan J, Basford J, Wampfler J, Garces Y . Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer. J Pain Symptom Manage. 2011; 42(2):202-12. PMC: 3381986. DOI: 10.1016/j.jpainsymman.2010.10.257. View

3.
Sarna L . Women with lung cancer: impact on quality of life. Qual Life Res. 1993; 2(1):13-22. DOI: 10.1007/BF00642885. View

4.
Lapid M, Rummans T, Brown P, Frost M, Johnson M, Huschka M . Improving the quality of life of geriatric cancer patients with a structured multidisciplinary intervention: a randomized controlled trial. Palliat Support Care. 2007; 5(2):107-14. DOI: 10.1017/s1478951507070174. View

5.
Rummans T, Clark M, Sloan J, Frost M, Bostwick J, Atherton P . Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol. 2006; 24(4):635-42. DOI: 10.1200/JCO.2006.06.209. View